Daniel P Oneill, MD
Cardiovascular Disease (Cardiology) · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Oneill’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A65286 · Current
Licensed to practise in California · since 1998 · expires 2028-03-31 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$245,592
Medicare paid this office $245,592 for 1,009 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 323 | $69,600 | $104 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 143 | $28,699 | $189 |
| Short return visit (20+ min) | 258 | $24,760 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $16,767 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $13,803 | $141 |
See all 25 services
| Return visit (30+ min) | 323 | $69,600 | $104 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 143 | $28,699 | $189 |
| Short return visit (20+ min) | 258 | $24,760 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $16,767 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $13,803 | $141 |
| New patient visit (60+ min) | 61 | $11,886 | $195 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 45 | $9,950 | $216 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $9,302 | $443 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 174 | $9,129 | $52 |
| Long return visit (40+ min) | 38 | $6,896 | $150 |
| New patient visit (45+ min) | 43 | $6,085 | $142 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 179 | $4,083 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 254 | $3,604 | $13 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 20 | $3,049 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $2,887 | $67 |
| Critical care, first 30-74 minutes | 12 | $2,805 | $175 |
| 3d radiographic procedure | 98 | $2,547 | $25 |
| Programming of dual lead pacemaker system | 15 | $2,297 | $79 |
| Ultrasound of heart blood flow, valves and chambers | 42 | $2,212 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 203 | $1,823 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 48 | $1,235 | $25 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 52 | $1,175 | $23 |
| Injection, regadenoson, 0.1 mg | 17 | $580 | None |
| Heart rhythm recording of continous external ekg over 8-15 days | 49 | $532 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $44 | $2 |
Who their Medicare patients are
1,009 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 22% · Women 48% · Also on Medicaid 41% · Health risk score 1.84. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 38% · Coronary heart disease 37% · Chronic kidney disease 36% · Atrial fibrillation 35% · Heart failure 33% · Depression 24% · COPD 18% · Cancer 16% · Dementia 16% · Stroke 13%.
The office billed $1,075,729, Medicare allowed $338,851 and paid $245,592; for 3,399 services of 47 kinds; $1,054 of it was for drugs given in the office and $244,537 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,009 | 3,399 | 77 | 1.84 | $1,075,729 | $245,592 |
| 2023 | 872 | 3,149 | 77 | 1.65 | $1,102,830 | $263,785 |
| 2022 | 949 | 3,495 | 76 | 1.79 | $1,228,102 | $309,300 |
| 2021 | 787 | 2,723 | 76 | 1.78 | $905,500 | $249,454 |
| 2020 | 598 | 2,882 | 76 | 1.65 | $645,960 | $192,970 |
| 2019 | 607 | 4,343 | 77 | 1.85 | $819,296 | $245,884 |
| 2018 | 595 | 5,395 | 77 | 1.88 | $905,854 | $279,422 |
| 2017 | 611 | 5,440 | 77 | 1.85 | $940,036 | $296,516 |
| 2016 | 622 | 5,997 | 78 | 1.87 | $931,295 | $292,764 |
| 2015 | 797 | 6,901 | 77 | 2.10 | $1,141,123 | $352,459 |
| 2014 | 931 | 5,274 | 78 | 2.10 | $969,058 | $315,115 |
| 2013 | 940 | 4,322 | 77 | 2.10 | $956,118 | $296,339 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 26 services
| Return visit (30+ min) | 375 | $90,894 | $103 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 121 | $25,051 | $199 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 42 | $19,893 | $474 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $19,851 | $107 |
| Short return visit (20+ min) | 173 | $15,189 | $73 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 91 | $14,111 | $147 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 156 | $9,129 | $57 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 34 | $7,639 | $225 |
| New patient visit (60+ min) | 38 | $7,617 | $200 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 43 | $6,606 | $77 |
| Long return visit (40+ min) | 32 | $6,482 | $162 |
| Injection, regadenoson, 0.1 mg | 38 | $5,923 | None |
| New patient visit (45+ min) | 41 | $5,811 | $142 |
| Critical care, first 30-74 minutes | 11 | $4,737 | $189 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 213 | $3,236 | $13 |
| Programming of dual lead pacemaker system | 19 | $2,449 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,286 | $69 |
| Ultrasound of heart blood flow, valves and chambers | 41 | $2,168 | $53 |
| 3d radiographic procedure | 67 | $1,683 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 150 | $1,340 | $7 |
| Injection, perflutren lipid microspheres, per ml | 16 | $1,120 | $35 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 47 | $1,082 | $23 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 42 | $1,075 | $26 |
| Heart muscle strain imaging | 16 | $625 | $39 |
| Heart rhythm recording of continous external ekg over 8-15 days | 43 | $482 | $11 |
| Injection, dobutamine hydrochloride, per 250 mg | 19 | $122 | None |
2022: 29 services
| Return visit (30+ min) | 380 | $120,192 | $105 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 138 | $28,752 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 109 | $22,057 | $93 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 45 | $21,580 | $480 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 96 | $16,972 | $166 |
| New patient visit (45+ min) | 96 | $13,545 | $141 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 177 | $10,940 | $59 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 39 | $9,169 | $235 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 48 | $8,424 | $88 |
| Critical care, first 30-74 minutes | 27 | $8,116 | $193 |
| Short return visit (20+ min) | 82 | $7,330 | $79 |
| Injection, regadenoson, 0.1 mg | 37 | $7,181 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 228 | $3,519 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,382 | $65 |
| Ultrasound of heart blood flow, valves and chambers | 51 | $2,703 | $53 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 14 | $2,698 | $193 |
| Transitional care management services for problem of at least moderate complexity | 13 | $2,584 | $199 |
| Programming of dual lead pacemaker system | 19 | $2,415 | $73 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 227 | $2,247 | $7 |
| Long return visit (40+ min) | 12 | $2,046 | $170 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 49 | $1,343 | $24 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 52 | $1,329 | $26 |
| Injection, perflutren lipid microspheres, per ml | 16 | $1,151 | $36 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,142 | $95 |
| Heart rhythm recording of continous external ekg over 8-15 days | 45 | $652 | $13 |
| 3d radiographic procedure | 25 | $621 | $23 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $212 | $16 |
| Injection, dobutamine hydrochloride, per 250 mg | 19 | $106 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $37 | $3 |
2021: 23 services
| Return visit (30+ min) | 310 | $114,874 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 137 | $29,248 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $15,492 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 79 | $13,525 | $169 |
| New patient visit (45+ min) | 77 | $11,064 | $144 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 165 | $10,236 | $60 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 41 | $10,013 | $244 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $4,670 | $67 |
| Long return visit (40+ min) | 25 | $4,659 | $166 |
| Critical care, first 30-74 minutes | 13 | $4,162 | $198 |
| Programming of dual lead pacemaker system | 23 | $3,528 | $74 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 224 | $3,426 | $13 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 16 | $3,199 | $200 |
| Short return visit (20+ min) | 23 | $1,810 | $75 |
| Ultrasound of heart blood flow, valves and chambers | 30 | $1,664 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 168 | $1,504 | $8 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 52 | $1,401 | $27 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,239 | $95 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 40 | $1,071 | $25 |
| Heart rhythm recording of continous external ekg over 8-15 days | 38 | $611 | $15 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $229 | $16 |
| Injection, dobutamine hydrochloride, per 250 mg | 11 | $67 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 13 | $40 | $3 |
2020: 18 services
| Return visit (30+ min) | 240 | $47,693 | $93 |
| Short return visit (20+ min) | 194 | $18,798 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $15,259 | $94 |
| Critical care, first 30-74 minutes | 14 | $13,656 | $198 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 61 | $11,802 | $190 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $11,679 | $182 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 148 | $9,630 | $63 |
| Subsequent nursing facility care with high level of medical decision making, per day at least 45 minutes | 12 | $9,178 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $8,267 | $66 |
| New patient visit (45+ min) | 56 | $7,615 | $136 |
| Programming of dual lead pacemaker system | 29 | $2,620 | $66 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 13 | $2,011 | $155 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 92 | $1,547 | $16 |
| Return visit (30+ min) | 16 | $1,471 | $70 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 53 | $857 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 32 | $336 | $8 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 16 | $288 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 16 | $193 | $12 |
2019: 27 services
| Short return visit (20+ min) | 281 | $46,443 | $60 |
| Return visit (30+ min) | 163 | $29,045 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 102 | $24,745 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 97 | $17,451 | $173 |
| Critical care, first 30-74 minutes | 28 | $16,497 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $14,253 | $168 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 176 | $11,746 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $10,208 | $87 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 19 | $9,546 | $502 |
| New patient visit (45+ min) | 60 | $8,374 | $140 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $5,174 | $235 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 19 | $3,683 | $97 |
| Programming of dual lead pacemaker system | 32 | $3,485 | $58 |
| Transitional care management services for problem of high complexity | 13 | $2,871 | $221 |
| Return visit (30+ min) | 28 | $2,269 | $69 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 12 | $1,822 | $152 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 97 | $1,465 | $6 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 16 | $1,241 | $78 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 19 | $1,158 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 57 | $1,087 | $16 |
| Long return visit (40+ min) | 11 | $1,046 | $95 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 37 | $881 | $23 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 19 | $701 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 26 | $485 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 26 | $336 | $13 |
| Blood test, clotting time | 11 | $304 | $4 |
| Infusion, normal saline solution, 250 cc | 19 | $9 | None |
2018: 28 services
| Short return visit (20+ min) | 289 | $38,937 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 118 | $36,510 | $65 |
| Return visit (30+ min) | 182 | $35,151 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $23,148 | $177 |
| Critical care, first 30-74 minutes | 29 | $17,202 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $16,973 | $92 |
| Subsequent nursing facility care with high level of medical decision making, per day at least 45 minutes | 14 | $14,181 | $123 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 28 | $14,026 | $501 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 68 | $12,135 | $169 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 148 | $9,684 | $62 |
| New patient visit (45+ min) | 56 | $7,675 | $137 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 28 | $5,345 | $95 |
| Return visit (30+ min) | 37 | $4,154 | $63 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 18 | $4,131 | $229 |
| Programming of dual lead pacemaker system | 32 | $2,901 | $48 |
| Transitional care management services for problem of high complexity | 13 | $2,848 | $219 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 100 | $2,199 | $6 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 12 | $1,801 | $150 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 28 | $1,686 | $60 |
| Short return visit (20+ min) | 29 | $1,363 | $31 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 61 | $1,088 | $16 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 28 | $945 | None |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $843 | $70 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 28 | $711 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 19 | $378 | $19 |
| Blood test, clotting time | 12 | $347 | $5 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 19 | $253 | $13 |
| Infusion, normal saline solution, 250 cc | 28 | $12 | None |
2017: 34 services
| Short return visit (20+ min) | 244 | $42,324 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 160 | $35,429 | $64 |
| Return visit (30+ min) | 145 | $27,223 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 133 | $26,440 | $174 |
| Critical care, first 30-74 minutes | 41 | $21,115 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $19,382 | $91 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 58 | $13,667 | $220 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 24 | $12,058 | $502 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 149 | $8,038 | $53 |
| New patient visit (45+ min) | 52 | $6,914 | $133 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 23 | $6,130 | $267 |
| Short return visit (20+ min) | 58 | $6,107 | $40 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $5,041 | $458 |
| Return visit (30+ min) | 42 | $4,822 | $68 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 11 | $4,771 | $84 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 24 | $4,580 | $95 |
| Transitional care management services for problem of high complexity | 14 | $3,287 | $219 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 144 | $3,168 | $6 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 13 | $2,948 | $227 |
| Programming of dual lead pacemaker system | 30 | $2,792 | $51 |
| Initial nursing facility care with high level of medical decision making, per day 50 minutes or more | 13 | $2,111 | $151 |
| Transitional care management services for problem of at least moderate complexity | 13 | $2,021 | $155 |
| New patient visit (45+ min) | 18 | $1,763 | $98 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $1,740 | $34 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 24 | $1,554 | $65 |
| Long return visit (40+ min) | 13 | $1,290 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 69 | $1,164 | $16 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 32 | $770 | $23 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 21 | $607 | None |
| Blood test, clotting time | 11 | $597 | $5 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 29 | $579 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 29 | $389 | $13 |
| Blood test, lipids (cholesterol and triglycerides) | 11 | $216 | $18 |
| Infusion, normal saline solution, 250 cc | 24 | $9 | None |
2016: 30 services
| Short return visit (20+ min) | 239 | $46,720 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 198 | $43,379 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 137 | $29,270 | $177 |
| Return visit (30+ min) | 137 | $25,790 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 102 | $20,243 | $92 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $18,421 | $512 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 63 | $14,707 | $226 |
| Critical care, first 30-74 minutes | 35 | $11,813 | $194 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 140 | $8,225 | $56 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 36 | $6,870 | $95 |
| Short return visit (20+ min) | 55 | $6,771 | $37 |
| New patient visit (45+ min) | 48 | $6,696 | $139 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 17 | $4,581 | $269 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 16 | $3,635 | $227 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 181 | $3,486 | $6 |
| Return visit (30+ min) | 35 | $3,287 | $61 |
| Programming of dual lead pacemaker system | 27 | $3,067 | $51 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 36 | $2,338 | $65 |
| Initial hospital care with same-day admission and discharge with moderate level of medical decision making, per day at least 70 minutes | 12 | $1,964 | $151 |
| New patient visit (30+ min) | 19 | $1,622 | $85 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 77 | $1,206 | $15 |
| New patient visit (45+ min) | 11 | $1,204 | $109 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 29 | $1,104 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $1,094 | $34 |
| Blood test, clotting time | 18 | $898 | $5 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 34 | $890 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 27 | $541 | $20 |
| Blood test, lipids (cholesterol and triglycerides) | 17 | $393 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 27 | $353 | $13 |
| Infusion, normal saline solution, 250 cc | 36 | $13 | None |
2015: 32 services
| Short return visit (20+ min) | 271 | $56,283 | $61 |
| Critical care, first 30-74 minutes | 70 | $51,628 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 189 | $45,943 | $64 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 52 | $26,593 | $511 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 121 | $24,386 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 97 | $19,491 | $93 |
| Return visit (30+ min) | 101 | $15,299 | $91 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 52 | $13,734 | $132 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 57 | $13,545 | $230 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 148 | $9,463 | $57 |
| New patient visit (45+ min) | 64 | $8,262 | $129 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 26 | $7,803 | $260 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 28 | $7,593 | $271 |
| Transitional care management services for problem of high complexity | 17 | $3,963 | $220 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 178 | $3,507 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 52 | $3,378 | $65 |
| Programming of dual lead pacemaker system | 31 | $3,094 | $51 |
| Short return visit (20+ min) | 30 | $2,491 | $44 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 231 | $2,318 | $8 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,757 | $103 |
| Transitional care management services for problem of at least moderate complexity | 11 | $1,616 | $147 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 31 | $1,521 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 85 | $1,441 | $16 |
| Blood test, clotting time | 17 | $807 | $5 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 29 | $522 | $18 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $453 | $35 |
| Insertion of needle into vein for collection of blood sample | 17 | $388 | $3 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 29 | $340 | $12 |
| Blood test, lipids (cholesterol and triglycerides) | 17 | $321 | $17 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $200 | $15 |
| Injection, aminophyllin, up to 250 mg | 14 | $35 | None |
| Infusion, normal saline solution, 250 cc | 52 | $16 | None |
2014: 29 services
| Short return visit (20+ min) | 264 | $58,391 | $62 |
| Critical care, first 30-74 minutes | 96 | $46,924 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 217 | $43,409 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 116 | $24,254 | $176 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 39 | $19,557 | $501 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 62 | $14,766 | $220 |
| New patient visit (45+ min) | 96 | $13,319 | $139 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 39 | $10,283 | $132 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 140 | $8,216 | $56 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 27 | $7,344 | $272 |
| Return visit (30+ min) | 53 | $6,468 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $5,094 | $91 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 17 | $4,591 | $270 |
| Programming of dual lead pacemaker system | 40 | $3,688 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 391 | $3,641 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 39 | $2,496 | $64 |
| Initial hospital observation care per day, typically 50 minutes | 19 | $2,175 | $114 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 23 | $1,948 | None |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,503 | $94 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 100 | $1,338 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 76 | $1,213 | $15 |
| Blood test, clotting time | 23 | $1,010 | $5 |
| Blood test, lipids (cholesterol and triglycerides) | 26 | $565 | $18 |
| Insertion of needle into vein for collection of blood sample | 23 | $564 | $3 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 14 | $278 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $249 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 15 | $209 | $13 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 12 | $116 | $10 |
| Infusion, normal saline solution, 250 cc | 39 | $13 | None |
2013: 29 services
| Critical care, first 30-74 minutes | 95 | $50,368 | $190 |
| Short return visit (20+ min) | 211 | $45,837 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 218 | $38,530 | $62 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $28,096 | $476 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 125 | $24,983 | $170 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 38 | $10,326 | $132 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 48 | $9,497 | $186 |
| New patient visit (45+ min) | 61 | $8,739 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $7,817 | $90 |
| Return visit (30+ min) | 54 | $7,382 | $97 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 122 | $7,002 | $53 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 24 | $6,229 | $260 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 21 | $6,199 | $61 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 27 | $4,985 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 464 | $4,180 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 37 | $2,542 | $67 |
| Programming of dual lead pacemaker system | 27 | $2,471 | $49 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 119 | $1,971 | $6 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,630 | $91 |
| Initial hospital observation care per day, typically 50 minutes | 13 | $1,519 | $117 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 19 | $1,226 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 55 | $1,157 | $18 |
| Follow-up observation care per day, typically 25 minutes | 13 | $875 | $58 |
| Blood test, clotting time | 20 | $751 | $5 |
| Blood test, lipids (cholesterol and triglycerides) | 40 | $605 | $11 |
| Liver enzyme (sgpt), level | 40 | $449 | $10 |
| Insertion of needle into vein for collection of blood sample | 20 | $417 | $3 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $226 | $16 |
| Infusion, normal saline solution, 250 cc | 26 | $28 | None |
Medicaid work
$19,828 in 2024
Medicaid paid $19,828 for 386 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 143 | $10,749 |
| Return visit (30+ min) | 96 | $6,387 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $1,389 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 110 | $1,211 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 24 | $92 |
| 2024 | 386 | 5 | 25 | $19,828 |
| 2023 | 440 | 5 | 26 | $32,433 |
| 2022 | 560 | 4 | 44 | $17,297 |
| 2021 | 726 | 5 | 39 | $25,912 |
| 2020 | 431 | 5 | 41 | $15,052 |
| 2019 | 718 | 4 | 54 | $29,317 |
| 2018 | 489 | 5 | 39 | $22,919 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 211 | $19,665 |
| Return visit (30+ min) | 103 | $9,748 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $1,606 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 86 | $1,101 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 28 | $315 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 161 | $11,530 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 320 | $3,474 |
| Return visit (30+ min) | 67 | $2,241 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 12 | $52 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 206 | $17,304 |
| Return visit (30+ min) | 133 | $3,789 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 287 | $3,320 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 22 | $891 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 78 | $607 |
2020
| Return visit (30+ min) | 298 | $10,667 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 70 | $3,739 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 25 | $455 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 15 | $144 |
| Rhythm ECG, 1-3 leads; interpretation and report only | 23 | $48 |
2019
| Return visit (30+ min) | 513 | $17,407 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 122 | $10,591 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 52 | $1,149 |
| Rhythm ECG, 1-3 leads; interpretation and report only | 31 | $171 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 111 | $10,139 |
| Return visit (30+ min) | 270 | $9,946 |
| Short return visit (20+ min) | 52 | $1,701 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 25 | $831 |
| Rhythm ECG, 1-3 leads; interpretation and report only | 31 | $302 |
Drugs they prescribed that Part D paid
$946,604
Pharmacies billed $946,604 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 5,022) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
4,265 generic and 757 brand-name prescriptions · $946,604 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 398 | $508,757 | $1,278 |
| Xarelto | 83 | $99,950 | $1,204 |
| Entresto | 53 | $81,778 | $1,543 |
| Repatha Sureclick | 68 | $63,557 | $935 |
| Jardiance | 45 | $45,340 | $1,008 |
See all 42 drugs
| Eliquis | 398 | $508,757 | $1,278 |
| Xarelto | 83 | $99,950 | $1,204 |
| Entresto | 53 | $81,778 | $1,543 |
| Repatha Sureclick | 68 | $63,557 | $935 |
| Jardiance | 45 | $45,340 | $1,008 |
| Brilinta | 27 | $21,893 | $811 |
| Amiodarone | 71 | $12,755 | $180 |
| Atorvastatin | 730 | $10,510 | $14 |
| Edarbi | 14 | $6,854 | $490 |
| Ezetimibe | 217 | $6,468 | $30 |
| Irbesartan | 332 | $6,465 | $19 |
| Amlodipine Besylate | 682 | $5,232 | $8 |
| Metoprolol | 273 | $4,590 | $17 |
| Hydralazine | 175 | $3,660 | $21 |
| Potassium Chloride | 137 | $2,881 | $21 |
| Bumetanide | 44 | $2,228 | $51 |
| Droxidopa | 12 | $2,226 | $185 |
| Midodrine | 12 | $2,155 | $180 |
| Losartan | 206 | $1,718 | $8 |
| Ranolazine Er | 14 | $1,613 | $115 |
| Rosuvastatin | 89 | $1,540 | $17 |
| Chlorthalidone | 90 | $1,459 | $16 |
| Lisinopril | 107 | $1,048 | $10 |
| Metoprolol | 160 | $972 | $6 |
| Olmesartan Medoxomil | 28 | $917 | $33 |
| Clopidogrel | 41 | $870 | $21 |
| Carvedilol | 87 | $833 | $10 |
| Furosemide | 118 | $781 | $7 |
| Propafenone | 13 | $769 | $59 |
| Benazepril | 42 | $759 | $18 |
| Flecainide Acetate | 15 | $622 | $41 |
| Spironolactone | 49 | $574 | $12 |
| Triamterene-Hydrochlorothiazid | 60 | $518 | $9 |
| Valsartan | 22 | $470 | $21 |
| Hydrochlorothiazide | 170 | $431 | $3 |
| Ramipril | 15 | $386 | $26 |
| Labetalol | 12 | $309 | $26 |
| Isosorbide Mononitrate Er | 22 | $251 | $11 |
| Pravastatin | 14 | $221 | $16 |
| Nitroglycerin | 12 | $181 | $15 |
| Torsemide | 13 | $130 | $10 |
| Clonidine | 19 | $48 | $3 |
Year by year
| 2024 | 5,022 | 647 | 0% (0) | 15% | $946,604 |
| 2023 | 4,460 | 533 | 0% (0) | 16% | $897,201 |
| 2022 | 4,131 | 510 | 0% (0) | 17% | $762,754 |
| 2021 | 3,723 | 465 | 0% (0) | 18% | $657,313 |
| 2020 | 3,283 | 420 | 0% (0) | 18% | $513,443 |
| 2019 | 3,571 | 391 | 0% (0) | 16% | $440,230 |
| 2018 | 3,747 | 382 | 0% (0) | None | $451,155 |
| 2017 | 3,337 | 337 | 0% (0) | None | $437,376 |
| 2016 | 2,814 | 288 | 0% (0) | None | $329,653 |
| 2015 | 2,199 | 259 | 0% (0) | None | $224,656 |
| 2014 | 1,933 | 224 | 0% (0) | None | $175,686 |
| 2013 | 2,512 | 205 | 1% (14) | 25% | $175,968 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 41 drugs
| Eliquis | 410 | $516,243 | $1,259 |
| Xarelto | 77 | $98,550 | $1,280 |
| Entresto | 27 | $50,652 | $1,876 |
| Jardiance | 44 | $38,158 | $867 |
| Repatha Sureclick | 42 | $30,954 | $737 |
| Brilinta | 28 | $22,787 | $814 |
| Amiodarone | 71 | $10,620 | $150 |
| Irbesartan | 274 | $10,156 | $37 |
| Atorvastatin | 581 | $9,561 | $16 |
| Pradaxa | 12 | $8,547 | $712 |
| Edarbi | 18 | $7,070 | $393 |
| Amlodipine Besylate | 660 | $6,431 | $10 |
| Hydralazine | 188 | $5,442 | $29 |
| Edarbyclor | 15 | $4,880 | $325 |
| Potassium Chloride | 118 | $4,661 | $40 |
| Ezetimibe | 100 | $4,592 | $46 |
| Metoprolol | 235 | $4,448 | $19 |
| Chlorthalidone | 131 | $3,564 | $27 |
| Midodrine | 12 | $3,337 | $278 |
| Losartan | 193 | $3,259 | $17 |
| Metoprolol | 170 | $2,219 | $13 |
| Bumetanide | 29 | $1,910 | $66 |
| Rosuvastatin | 84 | $1,660 | $20 |
| Carvedilol | 63 | $1,456 | $23 |
| Lisinopril | 113 | $1,246 | $11 |
| Clopidogrel | 44 | $1,105 | $25 |
| Benazepril | 42 | $1,036 | $25 |
| Furosemide | 100 | $765 | $8 |
| Triamterene-Hydrochlorothiazid | 44 | $746 | $17 |
| Flecainide Acetate | 18 | $729 | $40 |
| Valsartan | 16 | $673 | $42 |
| Olmesartan Medoxomil | 16 | $661 | $41 |
| Propafenone | 15 | $566 | $38 |
| Torsemide | 14 | $560 | $40 |
| Isosorbide Mononitrate Er | 18 | $520 | $29 |
| Ramipril | 16 | $418 | $26 |
| Spironolactone | 28 | $371 | $13 |
| Hydrochlorothiazide | 113 | $364 | $3 |
| Diltiazem 24hr Er (Cd) | 13 | $339 | $26 |
| Doxazosin Mesylate | 14 | $241 | $17 |
| Clonidine | 25 | $100 | $4 |
2022: 45 drugs
| Eliquis | 355 | $428,398 | $1,207 |
| Xarelto | 58 | $74,545 | $1,285 |
| Entresto | 28 | $49,914 | $1,783 |
| Repatha Sureclick | 46 | $29,773 | $647 |
| Brilinta | 37 | $28,090 | $759 |
| Jardiance | 26 | $19,016 | $731 |
| Pradaxa | 12 | $13,234 | $1,103 |
| Amiodarone | 69 | $9,575 | $139 |
| Irbesartan | 199 | $8,954 | $45 |
| Edarbyclor | 24 | $7,278 | $303 |
| Hydralazine | 243 | $6,662 | $27 |
| Atorvastatin | 389 | $6,434 | $17 |
| Edarbi | 17 | $6,249 | $368 |
| Chlorthalidone | 175 | $6,169 | $35 |
| Benicar | 11 | $5,454 | $496 |
| Amlodipine Besylate | 614 | $4,990 | $8 |
| Ezetimibe | 47 | $4,400 | $94 |
| Potassium Chloride | 101 | $3,847 | $38 |
| Metoprolol | 185 | $3,731 | $20 |
| Losartan | 204 | $2,658 | $13 |
| Midodrine | 18 | $2,230 | $124 |
| Rosuvastatin | 64 | $2,113 | $33 |
| Metoprolol | 197 | $2,004 | $10 |
| Carvedilol | 90 | $1,896 | $21 |
| Isosorbide Mononitrate Er | 19 | $1,542 | $81 |
| Clopidogrel | 52 | $1,519 | $29 |
| Lisinopril | 122 | $1,197 | $10 |
| Valsartan | 22 | $1,140 | $52 |
| Benazepril | 48 | $1,017 | $21 |
| Bumetanide | 19 | $873 | $46 |
| Labetalol | 13 | $859 | $66 |
| Triamterene-Hydrochlorothiazid | 53 | $836 | $16 |
| Furosemide | 100 | $715 | $7 |
| Diltiazem 24hr Er (Cd) | 18 | $615 | $34 |
| Klor-Con M20 | 12 | $519 | $43 |
| Lovastatin | 15 | $480 | $32 |
| Spironolactone | 40 | $431 | $11 |
| Nifedipine Er | 11 | $365 | $33 |
| Simvastatin | 16 | $292 | $18 |
| Quinapril | 17 | $287 | $17 |
| Hydrochlorothiazide | 99 | $269 | $3 |
| Doxazosin Mesylate | 13 | $264 | $20 |
| Diltiazem | 11 | $191 | $17 |
| Ramipril | 13 | $190 | $15 |
| Pantoprazole | 16 | $177 | $11 |
2021: 42 drugs
| Eliquis | 316 | $337,153 | $1,067 |
| Xarelto | 62 | $77,353 | $1,248 |
| Entresto | 33 | $51,147 | $1,550 |
| Brilinta | 27 | $21,187 | $785 |
| Repatha Sureclick | 29 | $19,201 | $662 |
| Edarbyclor | 40 | $12,425 | $311 |
| Multaq | 14 | $10,872 | $777 |
| Chlorthalidone | 276 | $10,003 | $36 |
| Amiodarone | 66 | $7,910 | $120 |
| Edarbi | 20 | $7,570 | $379 |
| Irbesartan | 151 | $7,289 | $48 |
| Hydralazine | 202 | $5,796 | $29 |
| Amlodipine Besylate | 549 | $5,507 | $10 |
| Atorvastatin | 246 | $4,636 | $19 |
| Potassium Chloride | 108 | $4,545 | $42 |
| Losartan | 186 | $3,115 | $17 |
| Metoprolol | 128 | $2,913 | $23 |
| Isosorbide Mononitrate Er | 28 | $2,312 | $83 |
| Carvedilol | 94 | $2,035 | $22 |
| Metoprolol | 196 | $1,837 | $9 |
| Rosuvastatin | 38 | $1,731 | $46 |
| Clopidogrel | 67 | $1,488 | $22 |
| Lisinopril | 149 | $1,369 | $9 |
| Valsartan | 18 | $1,364 | $76 |
| Valsartan-Hydrochlorothiazide | 12 | $1,258 | $105 |
| Diltiazem 24hr Er (Cd) | 27 | $1,250 | $46 |
| Labetalol | 15 | $1,007 | $67 |
| Omega-3 Acid Ethyl Esters | 11 | $847 | $77 |
| Losartan-Hydrochlorothiazide | 13 | $784 | $60 |
| Triamterene-Hydrochlorothiazid | 41 | $672 | $16 |
| Ezetimibe | 11 | $609 | $55 |
| Benazepril | 31 | $507 | $16 |
| Spironolactone | 47 | $490 | $10 |
| Torsemide | 18 | $416 | $23 |
| Ramipril | 18 | $375 | $21 |
| Furosemide | 67 | $370 | $6 |
| Lovastatin | 17 | $364 | $21 |
| Warfarin | 21 | $258 | $12 |
| Hydrochlorothiazide | 43 | $188 | $4 |
| Doxazosin Mesylate | 12 | $184 | $15 |
| Simvastatin | 18 | $184 | $10 |
| Clonidine | 14 | $61 | $4 |
2020: 41 drugs
| Eliquis | 227 | $241,463 | $1,064 |
| Xarelto | 91 | $79,437 | $873 |
| Entresto | 24 | $34,403 | $1,433 |
| Edarbyclor | 65 | $18,889 | $291 |
| Chlorthalidone | 310 | $14,249 | $46 |
| Brilinta | 18 | $13,006 | $723 |
| Edarbi | 21 | $8,144 | $388 |
| Pradaxa | 14 | $7,359 | $526 |
| Hydralazine | 170 | $6,037 | $36 |
| Atorvastatin | 190 | $5,167 | $27 |
| Amlodipine Besylate | 536 | $4,770 | $9 |
| Irbesartan | 79 | $4,382 | $55 |
| Pacerone | 17 | $4,379 | $258 |
| Amiodarone | 39 | $3,899 | $100 |
| Potassium Chloride | 101 | $3,856 | $38 |
| Ranolazine Er | 11 | $2,697 | $245 |
| Metoprolol | 84 | $2,556 | $30 |
| Isosorbide Mononitrate Er | 22 | $2,487 | $113 |
| Losartan | 128 | $2,432 | $19 |
| Carvedilol | 112 | $2,162 | $19 |
| Metoprolol | 164 | $1,704 | $10 |
| Midodrine | 19 | $1,644 | $87 |
| Diltiazem 24hr Er | 17 | $1,526 | $90 |
| Valsartan | 20 | $1,459 | $73 |
| Lisinopril | 162 | $1,454 | $9 |
| Clopidogrel | 78 | $1,450 | $19 |
| Rosuvastatin | 16 | $1,432 | $90 |
| Diltiazem 24hr Er (Cd) | 38 | $1,271 | $33 |
| Labetalol | 15 | $1,245 | $83 |
| Bumetanide | 26 | $1,110 | $43 |
| Lovastatin | 16 | $601 | $38 |
| Warfarin | 29 | $527 | $18 |
| Furosemide | 53 | $482 | $9 |
| Spironolactone | 40 | $471 | $12 |
| Benazepril | 41 | $355 | $9 |
| Torsemide | 14 | $251 | $18 |
| Hydrochlorothiazide | 24 | $227 | $9 |
| Triamterene-Hydrochlorothiazid | 19 | $196 | $10 |
| Ramipril | 11 | $176 | $16 |
| Simvastatin | 17 | $119 | $7 |
| Clonidine | 12 | $46 | $4 |
2019: 41 drugs
| Eliquis | 228 | $187,523 | $822 |
| Xarelto | 93 | $68,551 | $737 |
| Brilinta | 28 | $21,396 | $764 |
| Entresto | 11 | $14,988 | $1,363 |
| Edarbyclor | 42 | $13,234 | $315 |
| Chlorthalidone | 292 | $13,027 | $45 |
| Amiodarone | 56 | $6,418 | $115 |
| Atorvastatin | 205 | $6,256 | $31 |
| Ranolazine Er | 11 | $5,483 | $498 |
| Hydralazine | 180 | $4,817 | $27 |
| Bystolic | 11 | $4,538 | $413 |
| Amlodipine Besylate | 545 | $4,115 | $8 |
| Potassium Chloride | 72 | $3,766 | $52 |
| Irbesartan | 114 | $3,714 | $33 |
| Edarbi | 17 | $3,627 | $213 |
| Metoprolol | 97 | $3,492 | $36 |
| Diltiazem 24hr Er (Cd) | 31 | $2,541 | $82 |
| Isosorbide Mononitrate Er | 36 | $2,460 | $68 |
| Valsartan | 42 | $2,342 | $56 |
| Carvedilol | 156 | $2,080 | $13 |
| Losartan | 129 | $1,682 | $13 |
| Clopidogrel | 78 | $1,643 | $21 |
| Metoprolol | 154 | $1,569 | $10 |
| Bumetanide | 31 | $1,544 | $50 |
| Lisinopril | 188 | $1,466 | $8 |
| Nifedipine Er | 11 | $1,328 | $121 |
| Diltiazem 24hr Er | 17 | $1,264 | $74 |
| Rosuvastatin | 18 | $1,115 | $62 |
| Omega-3 Acid Ethyl Esters | 11 | $887 | $81 |
| Warfarin | 77 | $862 | $11 |
| Spironolactone | 96 | $763 | $8 |
| Minoxidil | 12 | $744 | $62 |
| Midodrine | 14 | $691 | $49 |
| Benazepril | 54 | $539 | $10 |
| Lovastatin | 16 | $483 | $30 |
| Furosemide | 50 | $376 | $8 |
| Hydrochlorothiazide | 39 | $318 | $8 |
| Triamterene-Hydrochlorothiazid | 12 | $204 | $17 |
| Simvastatin | 19 | $170 | $9 |
| Allopurinol | 17 | $130 | $8 |
| Dilt-Xr | 11 | $130 | $12 |
2018: 45 drugs
| Eliquis | 203 | $153,142 | $754 |
| Xarelto | 109 | $78,360 | $719 |
| Praluent | 22 | $26,061 | $1,185 |
| Brilinta | 23 | $20,910 | $909 |
| Chlorthalidone | 286 | $15,487 | $54 |
| Pradaxa | 12 | $9,678 | $807 |
| Entresto | 12 | $9,662 | $805 |
| Edarbyclor | 30 | $8,581 | $286 |
| Prasugrel | 19 | $8,577 | $451 |
| Atorvastatin | 202 | $5,815 | $29 |
| Valsartan | 124 | $5,403 | $44 |
| Amiodarone | 35 | $4,944 | $141 |
| Metoprolol | 133 | $4,668 | $35 |
| Amlodipine Besylate | 437 | $3,778 | $9 |
| Potassium Chloride | 60 | $3,134 | $52 |
| Isosorbide Mononitrate Er | 47 | $3,011 | $64 |
| Hydralazine | 160 | $2,989 | $19 |
| Rosuvastatin | 41 | $2,564 | $63 |
| Clopidogrel | 85 | $2,417 | $28 |
| Irbesartan | 74 | $2,118 | $29 |
| Carvedilol | 123 | $2,103 | $17 |
| Lisinopril | 257 | $1,891 | $7 |
| Metoprolol | 184 | $1,606 | $9 |
| Diltiazem 24hr Er (Cd) | 24 | $1,464 | $61 |
| Losartan | 97 | $1,243 | $13 |
| Warfarin | 97 | $1,123 | $12 |
| Amlodipine-Valsartan | 15 | $1,044 | $70 |
| Diltiazem 24hr Er | 22 | $1,022 | $46 |
| Nifedipine Er | 11 | $971 | $88 |
| Lovastatin | 27 | $929 | $34 |
| Amlodipine-Olmesartan | 11 | $719 | $65 |
| Pravastatin | 11 | $684 | $62 |
| Bumetanide | 19 | $661 | $35 |
| Spironolactone | 93 | $649 | $7 |
| Verapamil Er | 15 | $639 | $43 |
| Minoxidil | 15 | $590 | $39 |
| Benazepril | 37 | $420 | $11 |
| Hydrochlorothiazide | 68 | $346 | $5 |
| Furosemide | 59 | $280 | $5 |
| Simvastatin | 27 | $272 | $10 |
| Triamterene-Hydrochlorothiazid | 18 | $198 | $11 |
| Dilt-Xr | 14 | $184 | $13 |
| Ramipril | 15 | $174 | $12 |
| Losartan-Hydrochlorothiazide | 13 | $145 | $11 |
| Allopurinol | 18 | $104 | $6 |
2017: 45 drugs
| Eliquis | 208 | $133,837 | $643 |
| Xarelto | 89 | $66,864 | $751 |
| Praluent | 26 | $29,269 | $1,126 |
| Brilinta | 19 | $18,570 | $977 |
| Effient | 21 | $16,341 | $778 |
| Pradaxa | 16 | $15,829 | $989 |
| Repatha Sureclick | 13 | $14,939 | $1,149 |
| Chlorthalidone | 211 | $12,476 | $59 |
| Valsartan | 155 | $8,245 | $53 |
| Prasugrel | 12 | $5,799 | $483 |
| Metoprolol | 162 | $5,313 | $33 |
| Atorvastatin | 192 | $5,210 | $27 |
| Bystolic | 19 | $4,713 | $248 |
| Edarbyclor | 14 | $4,511 | $322 |
| Diltiazem 24hr Er | 60 | $4,222 | $70 |
| Potassium Chloride | 49 | $4,069 | $83 |
| Amiodarone | 25 | $3,872 | $155 |
| Verapamil | 14 | $2,696 | $193 |
| Amlodipine Besylate | 299 | $2,173 | $7 |
| Clopidogrel | 101 | $2,173 | $22 |
| Carvedilol | 130 | $2,090 | $16 |
| Metoprolol | 211 | $1,892 | $9 |
| Isosorbide Mononitrate Er | 49 | $1,791 | $37 |
| Lisinopril | 286 | $1,705 | $6 |
| Hydralazine | 105 | $1,662 | $16 |
| Minoxidil | 22 | $1,344 | $61 |
| Valsartan-Hydrochlorothiazide | 12 | $1,022 | $85 |
| Losartan | 76 | $952 | $13 |
| Rosuvastatin | 17 | $948 | $56 |
| Nifedipine Er | 11 | $901 | $82 |
| Warfarin | 83 | $891 | $11 |
| Amlodipine-Olmesartan | 11 | $791 | $72 |
| Sildenafil | 12 | $723 | $60 |
| Fenofibrate | 13 | $645 | $50 |
| Lovastatin | 16 | $579 | $36 |
| Pravastatin | 17 | $554 | $33 |
| Spironolactone | 40 | $409 | $10 |
| Benazepril | 38 | $363 | $10 |
| Hydrochlorothiazide | 47 | $237 | $5 |
| Losartan-Hydrochlorothiazide | 21 | $235 | $11 |
| Triamterene-Hydrochlorothiazid | 16 | $199 | $12 |
| Furosemide | 36 | $199 | $6 |
| Simvastatin | 22 | $180 | $8 |
| Allopurinol | 18 | $155 | $9 |
| Quinapril | 12 | $133 | $11 |
2016: 46 drugs
| Eliquis | 149 | $81,686 | $548 |
| Xarelto | 71 | $43,005 | $606 |
| Effient | 51 | $27,762 | $544 |
| Pradaxa | 23 | $14,326 | $623 |
| Diltiazem 24hr Er | 38 | $11,138 | $293 |
| Brilinta | 15 | $10,577 | $705 |
| Chlorthalidone | 148 | $8,801 | $59 |
| Valsartan | 128 | $8,588 | $67 |
| Multaq | 11 | $7,294 | $663 |
| Atorvastatin | 166 | $4,150 | $25 |
| Metoprolol | 126 | $4,146 | $33 |
| Amiodarone | 24 | $3,741 | $156 |
| Sildenafil | 24 | $2,573 | $107 |
| Edarbyclor | 13 | $2,381 | $183 |
| Potassium Chloride | 48 | $2,346 | $49 |
| Hydralazine | 66 | $2,155 | $33 |
| Clopidogrel | 81 | $2,029 | $25 |
| Amlodipine Besylate | 209 | $1,576 | $8 |
| Warfarin | 101 | $1,530 | $15 |
| Metoprolol | 159 | $1,342 | $8 |
| Lisinopril | 203 | $1,264 | $6 |
| Bumetanide | 19 | $1,230 | $65 |
| Omega-3 Acid Ethyl Esters | 14 | $1,225 | $87 |
| Carvedilol | 103 | $1,130 | $11 |
| Isosorbide Mononitrate Er | 27 | $999 | $37 |
| Torsemide | 18 | $940 | $52 |
| Valsartan-Hydrochlorothiazide | 13 | $788 | $61 |
| Fenofibrate | 13 | $691 | $53 |
| Metolazone | 12 | $664 | $55 |
| Losartan | 49 | $662 | $14 |
| Digox | 11 | $658 | $60 |
| Pravastatin | 18 | $651 | $36 |
| Minoxidil | 12 | $635 | $53 |
| Spironolactone | 33 | $489 | $15 |
| Nifedipine Er | 13 | $485 | $37 |
| Fludrocortisone Acetate | 13 | $380 | $29 |
| Enalapril Maleate | 12 | $377 | $31 |
| Hydrochlorothiazide | 55 | $344 | $6 |
| Benazepril | 39 | $336 | $9 |
| Simvastatin | 31 | $289 | $9 |
| Furosemide | 48 | $278 | $6 |
| Allopurinol | 16 | $271 | $17 |
| Triamterene-Hydrochlorothiazid | 19 | $255 | $13 |
| Ramipril | 13 | $245 | $19 |
| Quinapril | 12 | $138 | $12 |
| Pantoprazole | 12 | $124 | $10 |
2015: 38 drugs
| Xarelto | 84 | $47,034 | $560 |
| Eliquis | 50 | $27,542 | $551 |
| Effient | 41 | $24,180 | $590 |
| Pradaxa | 18 | $13,192 | $733 |
| Valsartan | 75 | $9,848 | $131 |
| Diltiazem 24hr Er | 19 | $7,918 | $417 |
| Crestor | 18 | $6,659 | $370 |
| Multaq | 11 | $5,247 | $477 |
| Diovan | 15 | $4,743 | $316 |
| Metoprolol | 104 | $4,468 | $43 |
| Bystolic | 17 | $3,817 | $225 |
| Potassium Chloride | 81 | $3,320 | $41 |
| Atorvastatin | 123 | $3,249 | $26 |
| Edarbyclor | 15 | $3,046 | $203 |
| Chlorthalidone | 47 | $2,592 | $55 |
| Warfarin | 112 | $2,229 | $20 |
| Amiodarone | 33 | $1,911 | $58 |
| Sildenafil | 16 | $1,601 | $100 |
| Clopidogrel | 76 | $1,533 | $20 |
| Hydralazine | 54 | $1,212 | $22 |
| Metoprolol | 128 | $1,166 | $9 |
| Celecoxib | 12 | $1,136 | $95 |
| Valsartan-Hydrochlorothiazide | 17 | $1,136 | $67 |
| Amlodipine Besylate | 132 | $1,084 | $8 |
| Lisinopril | 127 | $1,056 | $8 |
| Bumetanide | 29 | $1,028 | $35 |
| Digox | 21 | $895 | $43 |
| Carvedilol | 90 | $890 | $10 |
| Nifedipine Er | 17 | $540 | $32 |
| Spironolactone | 50 | $539 | $11 |
| Minoxidil | 11 | $506 | $46 |
| Furosemide | 57 | $486 | $9 |
| Benazepril | 47 | $466 | $10 |
| Isosorbide Mononitrate Er | 20 | $414 | $21 |
| Losartan | 24 | $366 | $15 |
| Hydrochlorothiazide | 46 | $308 | $7 |
| Simvastatin | 47 | $291 | $6 |
| Allopurinol | 20 | $244 | $12 |
2014: 37 drugs
| Xarelto | 90 | $42,435 | $471 |
| Diovan | 58 | $19,513 | $336 |
| Pradaxa | 37 | $17,935 | $485 |
| Effient | 12 | $7,036 | $586 |
| Metoprolol | 70 | $3,965 | $57 |
| Lovaza | 22 | $3,838 | $174 |
| Atorvastatin | 113 | $3,367 | $30 |
| Bystolic | 20 | $3,337 | $167 |
| Potassium Chloride | 66 | $2,994 | $45 |
| Clopidogrel | 65 | $2,498 | $38 |
| Celebrex | 12 | $2,490 | $207 |
| Bumetanide | 33 | $2,001 | $61 |
| Warfarin | 122 | $1,663 | $14 |
| Edarbyclor | 14 | $1,638 | $117 |
| Amiodarone | 18 | $1,575 | $88 |
| Sildenafil | 16 | $1,444 | $90 |
| Amlodipine Besylate | 131 | $1,342 | $10 |
| Chlorthalidone | 32 | $1,217 | $38 |
| Minoxidil | 24 | $1,177 | $49 |
| Hydralazine | 60 | $1,101 | $18 |
| Lisinopril | 97 | $1,033 | $11 |
| Metoprolol | 101 | $988 | $10 |
| Carvedilol | 65 | $876 | $13 |
| Digox | 22 | $762 | $35 |
| Valsartan-Hydrochlorothiazide | 18 | $750 | $42 |
| Isosorbide Mononitrate Er | 12 | $625 | $52 |
| Losartan | 26 | $613 | $24 |
| Simvastatin | 63 | $559 | $9 |
| Fenofibrate | 12 | $558 | $47 |
| Spironolactone | 23 | $524 | $23 |
| Hydrochlorothiazide | 60 | $468 | $8 |
| Benazepril | 43 | $454 | $11 |
| Nifedipine Er | 14 | $417 | $30 |
| Furosemide | 40 | $303 | $8 |
| Lovastatin | 12 | $274 | $23 |
| Klor-Con M15 | 12 | $199 | $17 |
| Clonidine | 11 | $141 | $13 |
2013: 53 drugs
| Pradaxa | 77 | $25,890 | $336 |
| Diovan | 65 | $22,685 | $349 |
| Xarelto | 25 | $10,169 | $407 |
| Niaspan | 23 | $7,738 | $336 |
| Budesonide | 12 | $7,235 | $603 |
| Atorvastatin | 138 | $5,778 | $42 |
| Lovaza | 28 | $4,510 | $161 |
| Metoprolol | 84 | $4,274 | $51 |
| Exelon | 12 | $3,908 | $326 |
| Clopidogrel | 60 | $3,781 | $63 |
| Bystolic | 18 | $3,188 | $177 |
| Namenda | 21 | $2,874 | $137 |
| Potassium Chloride | 79 | $2,558 | $32 |
| Hydralazine | 80 | $2,502 | $31 |
| Celebrex | 12 | $2,335 | $195 |
| Benicar | 15 | $2,297 | $153 |
| Zetia | 11 | $2,060 | $187 |
| Edarbyclor | 14 | $1,927 | $138 |
| Warfarin | 125 | $1,873 | $15 |
| Metoprolol | 169 | $1,661 | $10 |
| Amlodipine Besylate | 125 | $1,449 | $12 |
| Minoxidil | 21 | $1,435 | $68 |
| Fentanyl | 12 | $1,367 | $114 |
| Carvedilol | 67 | $1,222 | $18 |
| Olanzapine | 13 | $1,159 | $89 |
| Lisinopril | 101 | $1,062 | $11 |
| Hydrochlorothiazide | 96 | $1,041 | $11 |
| Fenofibrate | 15 | $994 | $66 |
| Simvastatin | 88 | $984 | $11 |
| Dexilant | 11 | $930 | $85 |
| Furosemide | 119 | $902 | $8 |
| Losartan | 27 | $887 | $33 |
| Sildenafil | 11 | $726 | $66 |
| Levothyroxine | 43 | $459 | $11 |
| Calcitriol | 12 | $459 | $38 |
| Omeprazole | 27 | $453 | $17 |
| Bumetanide | 17 | $427 | $25 |
| Latanoprost | 20 | $415 | $21 |
| Spironolactone | 15 | $413 | $28 |
| Ramipril | 22 | $385 | $18 |
| Amiodarone | 16 | $353 | $22 |
| Benazepril | 22 | $341 | $15 |
| Nitroglycerin Patch | 13 | $332 | $26 |
| Nifedipine Er | 12 | $306 | $25 |
| Digox | 23 | $304 | $13 |
| Hydroxyzine | 11 | $208 | $19 |
| Allopurinol | 30 | $200 | $7 |
| Klor-Con M15 | 11 | $183 | $17 |
| Trazodone | 20 | $179 | $9 |
| Escitalopram | 12 | $168 | $14 |
| Enalapril Maleate | 11 | $160 | $15 |
| Atenolol | 18 | $140 | $8 |
| Chlorhexidine Gluconate | 11 | $128 | $12 |
Money from drug and device companies
$97 in 2024
| 2024 | 1 | 1 | None | $97 |
| 2023 | 2 | 2 | None | $133 |
| 2022 | 2 | 2 | None | $46 |
| 2021 | 7 | 37 | None | $646 |
| 2020 | 18 | 132 | None | $2,101 |
| 2019 | 24 | 164 | None | $3,546 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $97 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2024-06-11 | None | $97 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $133
| Novo Nordisk | Wegovy | $125 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $8 | 1 payment
|
2022: $46
| Abbott Laboratories | Aveir | $25 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $21 | 1 payment
|
2021: $646
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $191 | 7 payments
|
| Chiesi USA | Kengreal | $175 | 14 payments
|
| Amarin Pharma | Vascepa | $154 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $47 | 2 payments
|
| Boston Scientific | Opticross | $39 | 2 payments
|
| Medtronic | In.Pact Admiral | $25 | 2 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $15 | 1 payment
|
2020: $2,101
| Chiesi USA | Kengreal 50mg/10ml L | $329 | 26 payments
|
| Amarin Pharma | Vascepa | $280 | 16 payments
|
| Janssen Pharmaceuticals | Xarelto | $274 | 17 payments
|
| Amgen | Corlanor | $257 | 13 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $208 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $191 | 9 payments
|
| Novartis Pharmaceuticals | Entresto | $112 | 8 payments
|
| Kowa Pharmaceuticals America | Livalo | $72 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $57 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $57 | 3 payments
|
| Pfizer | Eliquis | $56 | 2 payments
|
| Medtronic Vascular | In.Pact Admiral | $44 | 2 payments
|
| Lundbeck | Northera | $40 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $38 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $25 | 1 payment
|
| Astellas Pharma US | Lexiscan | $25 | 1 payment
|
| Boston Scientific | Rotablator | $21 | 1 payment
|
| Arbor Pharmaceuticals | Edarbi | $17 | 1 payment
|
2019: $3,546
| Amgen | Repatha | $794 | 28 payments
|
| Novartis Pharmaceuticals | Entresto | $379 | 22 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $297 | 10 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $279 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $271 | 14 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $224 | 13 payments
|
| Chiesi USA | Kengreal | $220 | 14 payments
|
| Janssen Pharmaceuticals | Xarelto | $193 | 11 payments
|
| Boston Scientific | Watchman | $134 | 5 payments
|
| Sanofi-Aventis U.S. | Praluent | $121 | 6 payments
|
| Actelion Pharmaceuticals US | Opsumit | $103 | 4 payments
|
| Philips Electronics North America | Igt D Peripheral | $87 | 2 payments
|
| Regeneron Healthcare Solutions | Praluent | $58 | 2 payments
|
| CathWorks | Ffrangio System | $51 | 2 payments
|
| Relypsa | Veltassa | $51 | 3 payments
|
| Pfizer | Eliquis | $45 | 2 payments
|
| Braemar Manufacturing | Cardiac Monitoring Suite | $41 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $40 | 1 payment
|
| Medtronic Vascular | Azure | $38 | 2 payments
|
| Abbott Laboratories | Confirm Rx | $35 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $30 | 1 payment
|
| Amarin Pharma | Vascepa | $24 | 1 payment
|
| Terumo Medical | Glidewire | $18 | 1 payment
|
| Arbor Pharmaceuticals | Edarbi | $13 | 1 payment
|
Professional record
- NPI
- 1477533461
- Licence
- CA A65286California A65286: Current · expires 2028-03-31
- Trained
- Georgetown University School of Medicine, 1996
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-01-18
- NPI last updated
- 2021-06-08
- NPI record certified
- 2021-06-08
This is when the NPI record was last certified, not a medical board exam.